BidaskClub Upgrades Agenus (NASDAQ:AGEN) to “Hold”
NASDAQ:AGEN remained flat at $$3.07 during trading hours on Tuesday. 48,660 shares of the company were exchanged, compared to its average volume of 744,833. The company has a market capitalization of $424.29 million, a price-to-earnings ratio of -2.13 and a beta of 1.84. The firm’s 50-day moving average price is $2.70 and its 200-day moving average price is $2.77. Agenus has a one year low of $1.54 and a one year high of $3.88.
Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.05). The company had revenue of $15.72 million for the quarter, compared to the consensus estimate of $5.37 million. Sell-side analysts expect that Agenus will post -1.04 earnings per share for the current fiscal year.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Article: How to track put option volume
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.